Bacteria have emerged as a potential vaccine for a rare blood condition that affects about 10,000 people worldwide, according to a new study.
The study also found that the vaccine could help people in other ways, such as helping people with asthma.
The findings are published online March 14 in the journal Science Translational Medicine.
Researchers from the University of Michigan, the University at Buffalo, and the University Hospitals of Vienna, Austria, tested the vaccine against a strain of coronaviruses and found that it caused only mild symptoms.
“We think the vaccine is safe for the general population, and we think it can be safe for people with specific genetic conditions,” said senior author John R. Linneman, MD, PhD, associate professor of infectious disease medicine at the University Hospital of Vienna and an associate professor in the Department of Molecular Microbiology at the Albert Einstein College of Medicine.
“In fact, it’s so safe that it could be given to children who have asthma and be safe, and it’s safe for those with COPD.”
He added that while there are still questions about whether the vaccine can help prevent severe infections and even death, the study shows that a vaccine that’s safe in general could be very effective in treating people with the rare condition.
The team’s findings have implications for people who suffer from other forms of viral illness, including coronaviral diseases such as HIV and the flu, which have a high risk of spread through sharing needles and coughing or sneezing.
For people who have been exposed to the virus, such exposure can trigger a host of symptoms, including fever, joint pain, muscle weakness, and skin rash.
“This means that people with these other forms will need additional support,” Linnemans said.
“It means you need to have support for people on the receiving end.”
Researchers at the university also looked at the effects of the vaccine on the immune system, which can help fight infection, and to assess the efficacy of the virus in reducing the symptoms of people with certain immune system conditions, such the common cold.
In addition, the researchers examined the impact of the treatment on patients with COPDs and chronic diseases, including asthma and rheumatoid arthritis.
In both cases, the vaccine was able to lower the virus’s ability to cause serious infections.
The researchers were able to identify and block certain genes from being expressed by a virus, which helped researchers identify and study them, said lead study author Emily M. Roussel, MD.
In the common disease group, the scientists found that after the vaccine treatment, the virus could be reduced to less than one-third of its normal levels.
This suggests that the virus can be less infectious and thus less likely to cause severe infections.
In some cases, patients showed more improvement in their COPD symptoms after the treatment, though not enough to recommend it for people suffering from the disease.
The new vaccine was designed to protect against the virus by inhibiting the virus’ ability to build up on the surface of cells, called capsid proteins, which make up most of the cell membrane.
These proteins were initially found to be very important in the production of proteins needed for the virus to survive, such that they could bind to a cell’s surface and keep it from being able to grow.
“They can block the viral replication by shutting down a particular gene,” Roussels said.
This led to a change in the way the virus was able of growing.
“So if you’re not using these capsid protein-based defenses to keep it alive, the infection can start to become more lethal,” Roudsel said.
The research team’s next step is to test the vaccine in humans with COPDS, and also in patients with chronic diseases.
“The next step we’re going to be looking at is to see if we can find out if the vaccine protects against COPD and other common conditions,” Rouxsel said, “and whether we can help people who are currently sick.”
The researchers are also working on ways to test a vaccine in people with other forms or other types of viral infections, such asthma, and other conditions.
For the new vaccine, the team focused on using capsid-related genes to prevent the virus from replicating.
They tested the vaccines in people who had been vaccinated with the flu vaccine and the coronavirin, a virus that kills many other coronavires.
The virus is also produced by coronavirosts, bacteria that live on the surfaces of certain kinds of viruses, such influenza and coronavire.
The vaccine also tested in mice and in people, and then tested in people using the influenza vaccine to see whether the vaccines prevented infection.
The scientists hope that their vaccine will be useful in other situations, including the development of a vaccine against an emerging strain of influenza that is more likely to be fatal.
The discovery of a new virus is a good thing, said study co-author Eric E. Roesch, PhD